|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009013,
umls-concept:C0018133,
umls-concept:C0026764,
umls-concept:C0030705,
umls-concept:C0040732,
umls-concept:C0439097,
umls-concept:C1280500,
umls-concept:C1333678,
umls-concept:C1547348,
umls-concept:C1552644,
umls-concept:C1705144,
umls-concept:C1705241,
umls-concept:C1823153,
umls-concept:C1841984,
umls-concept:C2349976,
umls-concept:C2732140
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-3-13
|
|
pubmed:abstractText |
TCR gamma/delta profiles were analyzed in 13 multiple myeloma patients after allogeneic non-myeloablative transplantation. Results show that both aGVHD and minimal residual disease (MRD) eradication did significantly affect TCR gamma/delta profile. During follow-up, six patients developed an aGVHD episode; in five of them, this event fitted with a modification of the TCR profile. Eleven patients achieved PCR-negativity during follow-up. In the 90% of them, the appearance of a new predominant TCR peak was concomitant to the disappearance of the IgH clone. These results suggest that different T gamma/delta populations would sustain GVM and GVH effects after non-myeloablative allogeneic transplant.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0145-2126
|
|
pubmed:author |
pubmed-author:BattollaBarbaraB,
pubmed-author:BenedettiEdoardoE,
pubmed-author:CiabattiElenaE,
pubmed-author:ConsoleGiuseppeG,
pubmed-author:CuzzolaMariellaM,
pubmed-author:FazziRitaR,
pubmed-author:GalimbertiSaraS,
pubmed-author:IacopinoPasqualeP,
pubmed-author:MartinoMassimoM,
pubmed-author:MorabitoFortunatoF,
pubmed-author:PapineschiFedericoF,
pubmed-author:PetriniIacopoI,
pubmed-author:PetriniMarioM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
529-35
|
|
pubmed:meshHeading |
pubmed-meshheading:16249028-Adult,
pubmed-meshheading:16249028-Aged,
pubmed-meshheading:16249028-Clone Cells,
pubmed-meshheading:16249028-Female,
pubmed-meshheading:16249028-Follow-Up Studies,
pubmed-meshheading:16249028-Graft vs Host Disease,
pubmed-meshheading:16249028-Graft vs Tumor Effect,
pubmed-meshheading:16249028-Humans,
pubmed-meshheading:16249028-Immunoglobulin Heavy Chains,
pubmed-meshheading:16249028-Male,
pubmed-meshheading:16249028-Middle Aged,
pubmed-meshheading:16249028-Multiple Myeloma,
pubmed-meshheading:16249028-Neoplasm, Residual,
pubmed-meshheading:16249028-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:16249028-Receptors, Antigen, T-Cell, gamma-delta,
pubmed-meshheading:16249028-Transplantation, Homologous,
pubmed-meshheading:16249028-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation.
|
|
pubmed:affiliation |
Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara, Via Roma, 56, 56100 PISA, Italy. s.galimberti@med.unipi.it
|
|
pubmed:publicationType |
Journal Article
|
